In 2017, the global human insulin (HI) market attained a value of $42.9 billion and is expected to advance at an 8.8% CAGR during the forecast period (2018–2023). The market is registering growth due to the surging geriatric population, rising exposure of people toward key risk factors resulting to diabetes, and increase in the number of diabetic patients. A type of synthetic insulin which mimics the insulin in humans is referred to as human insulin. Human insulin is generally created by growing insulin protein in bacteria, E. coli.